Hormone-Refractory Prostate Cancer: A Rational Approach to Chemotherapy
作者： Derek Raghavan
DOI: 10.1007/978-1-84628-738-1_31
关键词:
摘要: One of the important issues in use cytotoxic chemotherapy is timing treatment. When considering for “hormone-refractory” prostate cancer, one must ensure that cancer really resistant to impact castration. Adrenal androgens contribute hormonal environment, so some tumors appear be or refractory castrate, testoster-one-depleted setting, may actually receiving stimulation from adrenal hormones, and will thus respond second-line blockers, such as aminoglutethimide ketoconazole. These remissions sometimes sustained months years.
springer.com
sci-hub.st 参考文章(27)
F Nathan, C Khater, N Haas, M Cornfield, B Giantonio, R Greenberg, L Gomella, S Litwin, E Ross, S Roethke, C McAleer, G R Hudes, Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology. ,vol. 15, pp. 3156- 3163 ,(1997) , 10.1200/JCO.1997.15.9.3156
Philip W. Kantoff, Susan Halabi, Mark Conaway, Joel Picus, Jeffrey Kirshner, Vera Hars, Donald Trump, Eric P. Winer, Nicholas J. Vogelzang, Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study Journal of Clinical Oncology. ,vol. 17, pp. 2506- 2513 ,(1999) , 10.1200/JCO.1999.17.8.2506
I F Tannock, D Osoba, M R Stockler, D S Ernst, A J Neville, M J Moore, G R Armitage, J J Wilson, P M Venner, C M Coppin, K C Murphy, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Journal of Clinical Oncology. ,vol. 14, pp. 1756- 1764 ,(1996) , 10.1200/JCO.1996.14.6.1756
I F Tannock, Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate Journal of Clinical Oncology. ,vol. 3, pp. 1013- 1021 ,(1985) , 10.1200/JCO.1985.3.7.1013
David Osoba, Ian F. Tannock, D. Scott Ernst, Alan J. Neville, Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. Journal of Clinical Oncology. ,vol. 17, pp. 1654- 1654 ,(1999) , 10.1200/JCO.1999.17.6.1654
D. RAGHAVAN, L.J. BRANDES, K. KLAPP, T. SNYDER, E. STYLES, D. TSAO-WEI, G. LIESKOVSKY, D.I. QUINN, E.W. RAMSEY, Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. The Journal of Urology. ,vol. 174, pp. 1808- 1813 ,(2005) , 10.1097/01.JU.0000176799.63184.99
Howard I. Scher, William K. Kelly, Editorial: States and State Transitions are All That Really Matter The Journal of Urology. ,vol. 168, pp. 2451- 2453 ,(2002) , 10.1016/S0022-5347(05)64165-1
SHINJI URAKAMI, MIKIO IGAWA, NOBUYUKI KIKUNO, TATEKI YOSHINO, HIROFUMI KISHI, KAZUSHI SHIGENO, HIROAKI SHIINA, Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. The Journal of Urology. ,vol. 168, pp. 2444- 2450 ,(2002) , 10.1016/S0022-5347(05)64164-X
Daniel P. Petrylak, Catherine M. Tangen, Maha H.A. Hussain, Primo N. Lara, Jeffrey A. Jones, Mary Ellen Taplin, Patrick A. Burch, Donna Berry, Carol Moinpour, Manish Kohli, Mitchell C. Benson, Eric J. Small, Derek Raghavan, E. David Crawford, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer The New England Journal of Medicine. ,vol. 351, pp. 1513- 1520 ,(2004) , 10.1056/NEJMOA041318
WILLIAM BERRY, SHAKER DAKHIL, MANUEL MODIANO, MARYANN GREGURICH, LINA ASMAR, Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate Cancer The Journal of Urology. ,vol. 168, pp. 2439- 2443 ,(2002) , 10.1016/S0022-5347(05)64163-8